Eptaplatin - CAS 146665-77-2
Catalog number: 146665-77-2
Category: APIs
Molecular Formula:
Molecular Weight:
1. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer
Jin-Hee Ahn, Yoon-Koo Kang, Tae-Won Kim. Cancer Chemother Pharmacol(2002) 50: 104–110
Heptaplatin, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI-2053R, Sunpla) is a recently developed platinum derivative. In vitro studies have shown this new analogue to have high antitumor activity against various cancer cell lines, including cisplatin-resistant cancer cell lines. A preclinical study has also indicated that heptaplatin has a favorable toxicity profile in general pharmacological evaluation and that it might produce less nephrotoxicity than cisplatin. In a phase I clinical trial all three patients who received a dose of 480 mg/m2 heptaplatin developed severe nephrotoxicity (grade 2 azotemia and proteinuria), and the maximal tolerated dose was determined to be 480 mg/m2. A phase II study also demonstrated that this agent is active in the treatment of patients with advance gastric cancer (AGC) and has a favorable toxicity profile. In that study, the most common nonhematological toxicity was proteinuria (grade 1 or 2) seen in 80% of patients, but it was concluded that the proteinuria was mild and reversible.
2. Platinum‑based drugs: past, present and future
Shahana Dilruba • Ganna V. Kalayda. Cancer Chemother Pharmacol (2016) 77:1103–1124
Among other third-generation drugs, lobaplatin and heptaplatin received only regional approval. Lobaplatin (Fig. 1) is approved in China for the therapy of metastatic breast cancer, chronic myelogenous leukemia and SCLC. Its dose-limiting toxicity is thrombocytopenia. Heptaplatin (Fig. 1) has a bulkier amine ligand but is structurally similar to lobaplatin. The drug was demonstrated to be stable in solution, to have no remarkable toxicity and to retain cytotoxic activity in cisplatin-resistant cell lines. Heptaplatin is currently applied in the Republic of Korea for the treatment of gastric cancer. A Phase III study showed that heptaplatin combination with 5-luorouracil is comparable to cisplatin/5-luorouracil regimen with less severe hematological side effects.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 144689-63-4 Olmesartan MedoxoMil

Olmesartan MedoxoMil
(CAS: 144689-63-4)

CAS 98769-84-7 Reboxetine mesylate

Reboxetine mesylate
(CAS: 98769-84-7)

CAS 965-52-6 Nifuroxazide

(CAS: 965-52-6)

CAS 150399-21-6 Balsalazide disodium dihydrate

Balsalazide disodium dihydrate
(CAS: 150399-21-6)

Balsalazide disodium dihydrate is the disodium salt form of balsalazide which is a sulfasalazine analogue and can be synthesized from 4-aminobenzoyl-β-alanine (...

CAS 207844-01-7 Mitiglinide calcium hydrate

Mitiglinide calcium hydrate
(CAS: 207844-01-7)

Mitiglinide calcium hydrate, a derivative of benzylsuccinic acid, is a highly selective KATP channel antagonist.

CAS 153-61-7 Cephalothin

(CAS: 153-61-7)

CAS 39219-28-8 Promestriene

(CAS: 39219-28-8)

CAS 144598-75-4 Paliperidone

(CAS: 144598-75-4)

Chemical Structure

CAS 146665-77-2 Eptaplatin

Quick Inquiry

Verification code

Featured Items